文献速递慢性肾脏病肾血管病与高血压

戒烟与慢性肾脏病患者动脉粥样硬化心血管事件及死亡的关系

Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究 pooled KNOW-CKD 与 UK Biobank 共 66 245 例 CKD 患者及 307 353 例非 CKD 对照,中位随访 13.2 年。CKD 患者中,既往吸烟者与当前吸烟者主要结局风险分别较从不吸烟者高 1.30 倍和 2.14 倍;戒烟时间越长风险越低,但戒烟≥20 年者风险仍略高于从不吸烟者。

要点

  • CKD 患者中当前吸烟者主要结局风险为从不吸烟者的 2.14 倍。
  • 戒烟可降低风险,但 CKD 患者需更长戒烟时间才能抵消吸烟危害。
  • 吸烟负荷<20 包年者风险接近从不吸烟者,≥20 包年者风险显著升高。

核心结论

  • CKD 患者中,既往吸烟者与当前吸烟者动脉粥样硬化心血管事件或全因死亡复合结局风险均高于从不吸烟者。
  • 戒烟时间越长、吸烟负荷越低,主要结局风险越低,但 CKD 患者戒烟≥20 年者风险仍略高于从不吸烟者。

研究设计与样本

  • 研究汇总 KNOW-CKD 与 UK Biobank 队列共 66 245 例 CKD 患者,并纳入 UK Biobank 中 307 353 例非 CKD 参与者。
  • 根据问卷将参与者按吸烟剂量和戒烟持续时间分类,主要结局为动脉粥样硬化心血管事件或全因死亡的复合结局。

主要发现

  • 中位随访 13.2 年,14 671 例(22.1%)参与者达到主要结局。
  • CKD 汇总队列中,既往吸烟者和当前吸烟者主要结局风险分别较从不吸烟者高 1.30 倍和 2.14 倍。
  • 既往吸烟者中,吸烟负荷<20 包年和≥20 包年的 HR(95%CI)分别为 1.05(1.00-1.10)和 2.14(2.05-2.25)。
  • 与从不吸烟者相比,戒烟<10 年、10-20 年、≥20 年的 HR(95%CI)分别为 1.75(1.65-1.86)、1.43(1.34-1.52)、1.11(1.06-1.16)。
  • 非 CKD 人群中亦观察到类似关联,但戒烟≥20 年的既往吸烟者与从不吸烟者风险相当。

临床怎么用

  • 应将戒烟作为 CKD 患者降低动脉粥样硬化心血管事件和死亡风险的重要干预措施。
  • 对 CKD 患者应强调尽早戒烟并长期维持,以最大程度降低吸烟相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Smoking cessation is recommended to reduce excess atherosclerotic cardiovascular disease (ASCVD) and mortality in patients with chronic kidney disease (CKD). However, this recommendation is largely based on observational studies on the general population Therefore, we aimed to evaluate the association of smoking dose and smoking cessation duration with ASCVD and mortality in patients with CKD. METHODS: We compiled a comprehensive pooled dataset comprising 66 245 participants with CKD from the KNOW-CKD and the UK Biobank cohort. Additionally, we included 307 353 participants without CKD from the UK Biobank cohort. Participants were categorized according to smoking dose and duration of smoking cessation base on a questionnaire. The primary outcome was a composite of ASCVD events or all-cause mortality. RESULTS: Over a median follow-up period of 13.2 years, 14 671 (22.1%) participants reached the primary outcome. In the pooled CKD cohort, compared to never smokers, and former and current smokers exhibited a 1.30- and 2.14-fold higher risk of the primary outcome, respectively. Among former smokers, the hazard ratios (HRs) (95% confidence intervals [CIs]) for smoking loads <20 and ≥20 pack-years were 1.05 (1.00-1.10) and 2.14 (2.05-2.25), respectively. The increased risk of the primary outcome was attenuated by longer smoking cessation. The HRs (95% CIs) for smoking cessation of <10 years, 10-20 years, and ≥20 years were 1.75 (1.65-1.86), 1.43 (1.34-1.52), and 1.11 (1.06-1.16), respectively, compared with never smokers. This association was also observed in individuals without CKD, but the risk was comparable between former smokers with smoking cessation ≥20 years and non-smokers, suggesting that a longer cessation is required in patients with CKD to offset the smoking-related adverse effects. CONCLUSIONS: Among former smokers with CKD, the risk of ASCVD or mortality was substantially attenuated with less smoking load and a longer duration of smoking cessation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Joo YS, Yun HR, Kim HW, et al. Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39547936. doi:10.1093/ndt/gfae268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。